FDA Inspection 1056109 — Chongqing Daxin Pharmaceutical Co., Ltd.
The FDA completed an inspection of Chongqing Daxin Pharmaceutical Co., Ltd. on May 11, 2018 in Chongqing. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 11, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Chongqing (China)